Introduction
Adeno-associated viruses (AAVs) belong to the DNA parvovirinae family in the Dependovirus genus. 1 Some estimates suggest that as much as 80% of the human population is AAV seropositive 2, 3 ; however, the viruses are not known to cause morbidity, making them attractive agents for applications in human gene therapy. 1, 4 The biology of AAV, putative cellular receptors for uptake, and mechanism of transduction have been studied extensively, especially for AAV2, and reviewed in details elsewhere. 1, 4 Recombinant AAV (rAAV) vectors remain the most commonly used viral vectors in neuroscience research to achieve long-term and stable gene expression. 1, [4] [5] [6] Advances in recombinant DNA technology have provided a way to develop novel rAAV pseudotypes in which the genome and capsid components of different AAV viruses are co-packaged during virus production. For example, rAAV2/9 indicates that recombinant genome containing the AAV2-inverted terminal repeats is packaged in capsid derived from AAV9.
Recombinant AAV has been delivered into peripheral and central nervous system in vivo by multiple routes with variable transduction efficiencies. In adult nervous tissue, a common challenge is the efficient delivery of rAAV in select neuroanatomical areas, which is most commonly achieved by direct parenchymal (ie, intracerebral or intrathecal) injection. This mode of rAAV delivery is advantageous as it results in the highest gene expression at the site of injection, as well as 2 Neuroscience Insights circumvents unintended ectopic gene expression in systemic organs such as liver and heart. 1, 7, 8 However, this invasive approach is associated with tissue trauma and concurrent inflammation, which could be confounding factors (eg, especially in models of chronic neurological diseases), but may also affect transgene expression. 1, 4, 9 Therefore, there is burgeoning interest in evaluating minimally invasive approaches for rAAV-mediated gene delivery to nervous system by systemic inoculation (eg, rAAV9, 10 or recently AAV-PHB.eB and AAV-PHP.S 11 ).
Some rAAV capsid modifications have been shown to enhance their neuronal tropism and promote retrograde transduction (The term retrograde transduction in this manuscript refers to the uptake of injected rAAV particles at nerve terminals, retrograde transport, and subsequent transduction of nerve cell soma.) following peripheral routes of delivery (eg, subcutaneous, s.c.; intramuscular, i.m.; intra-organ, i.o.). 1 This could present an area in rAAV development that may tremendously advance their translational utility in neuroscience, especially if rAAV could be delivered locally at a peripheral site (eg, s.c.; i.m.) to target defined neuronal populations in peripheral and/or central nervous system. 1 Furthermore, a subset of promoters has been identified, which permits generalized transgene expression in transduced tissue (eg, cytomegalovirus [CMV] promoter) or cell-type-specific expression in neurons (eg, human synapsin promoter [hSyn]) or glia (eg, glial fibrillary acidic protein [GFAP] promoter). 12 The advantages of rAAV delivery using minimally invasive peripheral routes include not only achieving gene transfer in a targeted manner but also the avoidance of tissue trauma that may influence the gene expression and study outcomes.
Among the commonly used rAAV serotypes, rAAV2/6, 2/8, and 2/9 have been shown to transduce neurons in dorsal root ganglia (DRG) and spinal cord following peripheral routes of delivery, purportedly via retrograde transduction. [13] [14] [15] [16] These rAAV serotypes have been employed by multiple research groups for transgene overexpression or delivery of gene silencing constructs in vivo by direct intraparenchymal or peripheral routes. 1, 6, 12 However, an extensive side-by-side comparison of these 3 serotypes evaluating viral delivery into adult nervous tissue following a peripheral route of inoculation and the effect of promoter on transgene expression under identical experimental conditions has not been performed. In this proof-of-concept study, we performed a comparative evaluation of the 3 rAAV serotypes (ie, rAAV2/6, 2/8, and 2/9) encoding enhanced green fluorescent protein (eGFP -a useful marker widely used in similar studies for quantitative purposes and visualization 7, 13 ), which were delivered using a single unilateral hindlimb i.m. injection in adult wild-type C57BL/6J mice (see section 'Materials and Methods'). Enhanced green fluorescent protein transgene expression was driven under the control of either the CMV promoter (for achieving general transduction) or hSyn promoter (for achieving predominantly neuron-specific transduction), thus comparing the effect of these 2 widely used promoters. To increase the possibility of targeting multiple neuronal populations, we chose to deliver rAAV into mice by i.m. route as muscle tissue is highly innervated by components of both motor and sensory systems. We anticipate that our findings will serve as useful guide to researchers who aim to employ rAAV for localized gene transfer or modulating gene expression in select neuroanatomical tracts using peripheral routes of inoculation.
Materials and Methods

Recombinant AAV production
High-purity rAAV particles of the serotypes 2/6, 2/8, and 2/9 containing CMV:eGFP or hSyn:eGFP expression cassette flanked by AAV inverted repeats were obtained from the Iowa Vector Core, Iowa University, USA.
Animal studies
All procedures were performed in accordance with Danish National rules and the European Communities Council Directive for the care and handling of laboratory animals. Wildtype (C57BL/6J) mice, 3 to 4 months of age, were housed at the Aarhus University Bartholin animal facility under conditions of 12 h light/dark cycles and received ad libitum standard laboratory chow diet. Both male and female mice were used for analyses. Mice were anesthetized with isoflurane (1%-5%) inhalation and injected intramuscularly (i.m.) with rAAV particles (2.5e 10 viral particles, diluted in phosphate-buffered saline [PBS]) into the right hindlimb biceps femoris muscle unilaterally using a 10-μL Hamilton syringe (Model #801 RN) with a 25-gauge needle (n = 6/group). To ensure adequate inoculation, rAAV particles were injected at 3 sites in the muscle (upper part, centre of the muscle belly, and lower part) with injection volume not exceeding 3 µL at each site. A gentle massage on the muscle was performed to facilitate the diffusion of viral particles, 17 and the mice were allowed to recover under close observation before returning to their original cage. Four weeks after the rAAV injection, the mice were terminally anaesthetized i.p. with sodium pentobarbital (100 mg/kg) followed by transcardiac perfusion with ice cold PBS containing 10 000 units/L heparin (Sigma, #H3393). Then, tissues including hindlimb biceps femoris muscle (right and left sides), sciatic nerve (right and left sides, segment between sciatic notch and trifurcation in popliteal fossa), L4-L5 DRG (right and left sides), spinal cord, brain, and liver were dissected. For collecting spinal cord and subsequent dissection of DRG, an improved method based on the hydraulic extrusion of spinal cord was employed, which minimizes tissue handling and maintains the DRG integrity. 18 For the determination of viral genome in the tissue and gene expression studies (see in the following), the tissues were transferred into cryogenic vials and fresh frozen in liquid nitrogen Jan et al 3 (n = 3/group). In parallel, harvested tissues were fixed in 4% paraformaldehyde (in PBS) overnight at 4ºC and embedded in paraffin blocks for immunohistochemical analysis as outlined in the following (n = 3/group).
Quantitative polymerase chain reaction
For the determination of viral genome in tissue, genomic DNA was extracted from the fresh frozen tissue using a commercial kit (#K0721; Thermo Fisher) following the manufacturer's protocol. Genomic DNA (10 ng) was amplified with SYBR green (#4385616; Thermo Fisher) using primers targeting SV40 polyA in CMV:eGFP (forward, 5′-TGGACAAACCA CAACTAGAATGCAG-3′; reverse, 5′-CTCCCACACCT CCCCCTGAA-3′) or bovine growth hormone polyA in hSyn:eGFP (forward, 5′-CCGTGCCTTCCTTGACC CTG-3′; reverse, 5′-TCCCAATCCTCCCCCTTGCT-3′), and using mouse β-tubulin (Tubb2b) as internal control (forward, 5′-GCCAGAGTGGTGCAGGAAATA-3′; reverse, 5′-TCACCACGTCCAGGACAGAGT-3′). All the samples were run in duplicates per experiment and average values were used for analyses. Vector genome copies were expressed for 2N genomes according to the β-tubulin copy number measured in the same sample (2 β-tubulin gene copies/cell genome 19 ). For the determination of eGFP mRNA expression, total RNA was extracted from the fresh frozen tissue using QIAzol lysis reagent (#74134; Qiagen) and purified using a commercial kit (#74134; Qiagen). Complementary DNA (cDNA) was synthesized using high-capacity reverse transcriptase kit (#4368814; Applied Biosystems). Quantitative polymerase chain reaction (qPCR) was performed using SYBR green (#4385616; Thermo Fisher) under standard conditions with primers targeting eGFP (forward, 5′-TGACCCTGAA GTTCATCTGCACCA-3′; reverse, 5′-TCTTGTAGTTG CCGTCGTCCTTGA-3′) and mouse gapdh (forward, 5′-CCCTTAAGAGGGATGCTGCC-3′; reverse, 5′-TAC GGCCAAATCCGTTCACA-3′). The samples were run in duplicates per experiment and average values were used for analyses. The data were analysed by relative ΔΔCT relative quantification method 20 
Immunofluorescence microscopy
Paraffin embedded tissues were sectioned (10 µm section thickness) and mounted on superfrost slides. After deparaffinization and antigen retrieval in citrate buffer pH 6.0, immunofluorescence staining on sections was performed using rabbit polyclonal GFP antibody (#2555, 1:1000 dilution; Cell Signalling Technologies) with Alexa Fluor 488 conjugated goat anti-rabbit secondary antibody (#A-11034, 1:200 dilution; Thermo Fisher), to unambiguously detect eGFP transgene expression and differentiate from tissue background fluorescence. 8, 14 The slides were mounted using a mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) nuclear stain (Fluoro-Gel II, #17985; Electron Microscopy Sciences), and the slides were dried and sealed. Image acquisition was performed using a Zeiss fluorescence microscope under identical conditions (20× objective; laser intensity 30%; DAPI exposure time, 50 ms; GFP exposure time, 300 ms). Lumbar spinal cord sections were additionally co-stained for neuronal nuclei protein NeuN using mouse monoclonal NeuN antibody (#MAB377, 1:1000 dilution; Millipore) with Alexa Fluor 568-conjugated goat anti-mouse secondary antibody (#A-11031, 1:200 dilution; Thermo Fisher). The slides were then scanned using NanoZoomer S60 digital slide scanner (Hamamatsu).
Statistics
Quantitative PCR data were analysed in GraphPad Prism software and graph plots were prepared in Microsoft Excel. Data are expressed as arithmetic mean ± standard error of mean (s.e.m.). Statistical differences in multiple group comparisons were assessed by one-way analysis of variance (ANOVA) post hoc Bonferroni test. Pair-wise comparisons were further assessed by Mann-Whitney test, as indicated in figure legends. The alpha level of statistical significance was set at P = .05.
Results
rAAV genome was largely detected in the injected muscle and ipsilateral sciatic nerve post injection in hindlimb biceps femoris muscle
To compare the uptake of rAAV serotypes 2/6, 2/8, and 2/9 at the local nerve endings in the muscle and subsequent spreading into the connected nervous structures (as has been proposed for these rAAV serotypes 13, 15, 21 ) , we quantified the rAAV viral genome in different tissues 4 weeks post-i.m. injection (unilateral right hindlimb biceps femoris muscle) in wild-type (C57BL/6J) mice. The rodent sciatic nerve is the largest sensory-motor spinal nerve, and its branches are located deep in the upper hindlimb between the heads of biceps femoris muscle. Accordingly, we investigated the degree of rAAV spreading and transduction efficiency of these select rAAV serotypes into sciatic nerve, L4-L5 DRG (corresponding to the roots of sciatic nerve), lumbar spinal cord, and brain (whole brain homogenate) following i.m. injection. As haematogenous spreading of rAAV6 and rAAV9 has also been reported following i.m. injection in mice, 14, 16 assessment of viral dissemination to liver was also included as a control measurement.
Our results show that the bulk of viral load was detected in the injected biceps femoris muscle, regardless of the rAAV serotype or promoter (ie, CMV or hSyn; Figure 1A ). Nevertheless, compared to the un-injected side, significant viral genome could also be detected in sciatic nerve ( Figure 1B ) and L4-L5 DRG ( Figure 1C) with all the rAAV serotypes tested and was particularly pronounced with rAAV serotypes 2/6 and 2/8. Minimal rAAV viral genome was detected in the lumbar segment of spinal cord or brain in all groups ( Figure 1D and E), suggesting limited rAAV spreading. Of the select serotypes, only rAAV2/9 exhibited significant presence of viral genome in the liver ( Figure 1F ), and this is not surprising as muscle is a highly vascularised tissue and haematogenous spreading of rAAV9 is well known. 8, 22 These data (Figure 1 , also see Table 1) show that although the rAAV genome was predominantly detected in the injected biceps femoris muscle, the select rAAV serotypes exhibited noticeable degree of spreading into the local nervous tissues, particularly into the sciatic nerve and DRG. Intramuscular injection of rAAV2/6, 2/8, or 2/9 expressing eGFP under CMV promoter (CMV:eGFP) efficiently transduces biceps femoris muscle and local nervous structures Then, we wanted to evaluate transduction efficiency, as well whether transgene (ie, eGFP mRNA) expression is influenced by CMV or hSyn promoter in the tissues. We found that the select rAAV serotypes (CMV:eGFP) i.m. inoculation resulted in robust eGFP transgene expression in the ipsilateral biceps femoris muscle of all animals (Figure 2A ). In addition, all the tested serotypes caused enhanced eGFP mRNA expression in the ipsilateral (IL) sciatic nerve and L4-L5 DRG compared to the contralateral (CL) side. Specifically, there was >20-fold increase in eGFP mRNA in the sciatic nerve, which was more pronounced with rAAV2/6 ( Figure 2B ). In the L4-L5 DRG, there was ~2-to 3-fold increase in eGFP mRNA expression in all samples ( Figure 2C ). In the spinal cord lumbar segment, minimal eGFP mRNA expression was detected, with only rAAV2/6 leading to noticeable expression (~5-to 6-fold; Figure 2D ). In addition, there was no detectable eGFP mRNA in brain or liver ( Figure 2D ). These data show that eGFP expression was predominantly localized in the biceps femoris muscle and sciatic nerve on the injected side, with comparatively lower expression in ipsilateral DRG (compare Figure 2A and B and C and D).
Next, we examined the eGFP epifluorescence (reflecting protein expression) in these tissues by immunofluorescence microscopy. Supporting the data in Figures 1A and B and 2A and B, clear eGFP epifluorescence was observed in the ipsilateral biceps femoris muscle ( Figure 3A ; compare CL muscle, Figure S1a ) and sciatic nerve ( Figure 3B ; compare CL nerve, Figure S1b ). In ipsilateral L4 DRG, large neuronal bodies were seen to be eGFP positive, particularly in mice inoculated with rAAV2/6 and 2/8 (CMV:eGFP); albeit, many DAPI-labelled cells lacking detectable eGFP epifluorescence were also observed ( Figure 3C ; compare CL DRG, Figure S1a ). Supporting the data on low levels of eGFP expression in lumbar cord ( Figure 2D ), sparse eGFP epifluorescence was observed bilaterally in ventral horn (VH) and dorsal horn (DH), particularly with rAAV2/6 and rAAV2/9 ( Figure 4A and C, respectively), predominantly in a pattern resembling neuronal processes. eGFP fluorescence in rAAV2/8 groups was remarkably absent ( Figure 4B ). These observations are similar to previous studies showing minimal eGFP expression in CL DRG or spinal cord following i.m. injections with rAAV2/6 and 2/8 in adult rodents 14, 15 or in non-human primates. 13 
Biceps femoris muscle injection of rAAV2/6, 2/8, or 2/9 expressing eGFP under human synapsin promoter (hSyn:eGFP) efficiently transduces local nervous structures
Next, we analysed eGFP mRNA and eGFP epifluorescence in the tissues subsequent to biceps femoris muscle i.m. injection with the select rAAV serotypes expressing eGFP under Neuroscience Insights the control of hSyn promoter (hSyn:eGFP). We found significantly increased eGFP mRNA in the injected muscle (5to 25-fold, Figure 4A ), although not as pronounced as seen with rAAV expressing eGFP under CMV promoter (1300to 2100-fold; compare Figures 2A and 5A ). Furthermore, there was a significantly larger increase in the eGFP mRNA in the ipsilateral sciatic nerve, particularly with rAAV2/6 (~1900-fold) and rAAV2/8 (~140-fold) in hSyn:eGFP groups compared to CMV:eGFP groups (compare Figures  2B and 5B ). We also observed 2-to 3-fold increased eGFP mRNA expression in ipsilateral DRG, particularly with rAAV2.6 and 2/8 ( Figure 5C ). In the lumbar spinal cord, rAAV2/6 led to a robust (~15-fold) increase in eGFP mRNA expression, followed by rAAV2/9 (~5-fold; Figure 5D ). In addition, eGFP mRNA was not detectable in brain or liver tissue ( Figure 4D ). Subsequent eGFP immunofluorescence analyses showed that in the ipsilateral muscle tissue, muscle cell cytoplasm exhibited minimal eGFP epifluorescence, and the pattern of intense eGFP signal on/around the surface of muscle fibres was reminiscent of nerve terminals in the muscle ( Figure 6A ; compare CL muscle, Figure S1a ). There was visibly pronounced eGFP signal in the ipsilateral sciatic nerve, especially with rAAV2/6 ( Figure 6B ; compare CL nerve, Figure S1b ). As seen with rAAV-CMV:eGFP ( Figure  3C ), eGFP-positive large neuronal cell bodies in the ipsilateral L4 DRG could be distinguished ( Figure 6C ; compare CL DRG, Figure S1c ). The lumbar spinal cord showed less pronounced eGFP fluorescence, which was scattered bilaterally in both VH and DH, and highlighted neuronal processes (rAAV2/6 and rAAV2/9; Figure 7A and C, respectively). Lumbar cord section from rAAV2/8 mice was largely devoid of any detectable eGFP fluorescence ( Figure 7B ). Overall, these data suggest limited rAAV transport from i.m. site into lumbar spinal cord regardless of the serotypes used in this study or promoter, with the exception of rAAV2/6 which led to 5-to 15-fold increase in eGFP mRNA expression ( Figures  2D and 5D ) and appreciable eGFP fluorescence ( Figures 4A  and 7A ). 
Discussion
Harnessing the capability of some rAAV serotypes for retrograde transduction, 13, 15 whereby the rAAV particles are taken up at the nerve endings and spread in connected neuroanatomical tracts, and evolving the rAAV design to improve such capability (as exemplified recently with rAAV-retro), 23 present promising means of targeted gene transfer in peripheral and central nervous system. Our data show that subsequent to a single i.m. injection in hindlimb biceps femoris muscle of adult mice with 3 select neurotrophic rAAV serotypes (ie, rAAV2/6, 2/8 and 2/9), viral genome and transgene expression (ie, eGFP) was predominantly detected in the injected muscle and ipsilateral sciatic nerve (Figures 1, 2, and 5 ). Compared to these tissues, substantially less viral load and low expression of eGFP mRNA were detected in the ipsilateral spinal L4-L5 DRG and lumbar spinal cord. Fluorescence microscopy analyses revealed that the eGFP immunofluorescence was predominantly localized in large neuronal cell bodies in ipsilateral DRG (Figures 3   and 6 ). In the lumbar spinal cord, scant but discernible eGFP signal could be observed bilaterally, particularly with rAAV2/6 and rAAV2/9 (Figures 4 and 7) . Our data suggest that rAAV spreading following i.m. delivery, and transgene (eGFP) expression in injected muscle and nervous tissue, occurred in a manner that reflects nervous supply (motor and sensory) to the biceps femoris muscle. Furthermore, the tissue in immediate vicinity (sciatic nerve) showed higher viral load and eGFP expression than relatively distant locations (DRG, spinal cord, and brain), hence indicating rAAV spreading in connected local neuroanatomical tracts and little or no contribution by other routes of spreading (eg, haematogenous spreading -as has been reported for rAAV2/9). It has been suggested that rAAV can retrogradely target DRG through sensory nerve endings in the intrafusal muscle fibres. 14 Furthermore, ~60% of the nerve fibres in muscle are projections from alpha and gamma motor neurons in the VH of spinal cord and that may explain predominant eGFP localization Figure S1 containing data for contralateral side (rAAV2/6-CMV:eGFP). CMV indicates cytomegalovirus promoter; DRG, dorsal root ganglia; eGFP, enhanced green fluorescent protein; rAAV, recombinant adeno-associated virus.
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in distinct neuronal populations and neuroanatomical tracts in our study (Figures 3, 4, 6, and 7) and by others. 13 Our observations are also in line with published reports individually employing the select rAAV serotypes, delivered in vivo via peripheral routes, for gene transfer in DRG or spinal cord. For instance, i.m. inoculation in adult mice with rAAV2/8 encoding eGFP under the control of CMV promoter (CMV:eGFP) has been shown to transduce peripheral nerves in the injected muscle as well as ipsilateral DRG, albeit with limited eGFP expression in spinal cord. 15 Another study compared the rAAV2/6 (CMV:eGFP) viral load and eGFP expression subsequent to s.c. or hindlimb i.m. injection with direct sciatic nerve or intrathecal delivery in spinal cord in adult mice. 14 As expected, the direct modes of delivery resulted in high efficiency, and the authors also found viral delivery in nociceptive neurons in DRG and motor neurons in the lower segments of spinal cord following s.c. or i.m. delivery. 14 In a related study, the same authors also demonstrated robust induction of eGFP expression in motor neurons in the ipsilateral lumbar segments of spinal cord subsequent to a single hindlimb i.m. rAAV2/6 (CMV:eGFP) injection in African green monkeys, somewhat recapitulating the observations in rodents. 13 A limited number of additional studies have also explored the transduction of nervous tissues in animal models following peripheral rAAV administration of rAAV1, rAAV2, rAAV9, and self complimentary rAAV vectors. [24] [25] [26] [27] [28] [29] [30] These latter studies also showed various degrees of rAAV spreading from the injection site reliant on, 'hijacking' the axonal transport machinery, and transduction of neurons in DRG and motor neurons in spinal cord. [24] [25] [26] [27] The lack of widespread dissemination of rAAV following i.m. delivery may be advantageous in studies aimed at targeting local nerve structures, albeit rAAV would have to be delivered bilaterally (for instance, CL nerve or DRG do not show significant viral load or lack of eGFP expression in this study). In addition, our results also show a lack of viral genome or eGFP gene expression in brain, suggesting that the lower limb i.m. delivery route and transport via spinal nerves may not be ideal for that purpose. It would be interesting to determine whether rAAV injections in the territory of a cranial nerve in head and 
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Neuroscience Insights neck region can lead to rAAV spreading into targeted areas in brain due to proximity (ie, shorter neural tracts). Alternatively, it is also worthwhile to investigate the utility of smooth muscle injections in the territory of large cranial nerve such as vagus in gene transfer into brain, particularly with the refined rAAV pseudotypes, for example, AAV-PHB.eB and AAV-PHP.S 11 and rAAV2-retro. 23 Apart from the research utility in basic neuroscience studies, our findings encourage rAAV-mediated disease model development or gene delivery in some models of neurological diseases, for example: (1) rAAV i.m. delivery, particularly with rAAV2/6 and 2/8, can be used for gene transfer in the peripheral nervous system in a targeted manner such that only the local nerves and DRG are transduced. 14 This can be useful in interrogating function of specific genes in models of sensory dysfunction such as neuropathic pain, or for therapeutic gene delivery following nerve injury, and possibly in models of demyelinating diseases, and (2) in models of chronic neurodegenerative diseases such as Parkinson disease, where misfolded forms of protein aggregates are putatively thought to originate in periphery and spread from peripheral to central nervous system. 31 In such models, rAAV could be useful in blocking the expression of genes favouring the spreading of misfolded proteins in neuroanatomical tracts affected early in the pathogenesis, as well as for delivering protective genes in peripheral nerves to prevent the toxicity of misfolded protein aggregates originating in periphery.
In conclusion, we compared 3 common rAAV serotypes (rAAV2/6, 2/8, and 2/9 -CMV or hSyn promoter), which have been shown to transduce nerve structures following peripheral routes of delivery, and confirm their utility in achieving gene transfer in local neuroanatomical tracts following hindlimb i.m. inoculation. However, further refinements in rAAV design, combined with alternative strategies in i.m. delivery, maybe required for this route to be satisfactorily useful in targeting selected neuronal populations in spinal cord and brain. Figure S1 containing data for contralateral side (rAAV2/6-hSyn:eGFP). DRG indicates dorsal root ganglia; eGFP, enhanced green fluorescent protein; hSyn, human synapsin promoter; rAAV, recombinant adeno-associated virus.
